CAMBRIDGE, Mass.--(BUSINESS WIRE)--Oct. 1, 2013--
Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), today announced that the
company has been added to the Russell 2000®, Russell 3000® and Russell
Global® Indexes as part of Russell Investments’ third-quarter IPO
additions that took place after market close on September 30, 2013.
The Russell 2000® Index measures the performance of the small-cap
segment of the U.S. equity market and is a subset of the Russell 3000®,
representing approximately 10 percent of the total market capitalization
of that index. Membership in the Russell 2000® Index includes automatic
inclusion in the appropriate growth and style indexes.
Russell indices are widely used by investment managers and institutional
investors for index funds and as benchmarks for both passive and active
investment strategies. Russell Investments determines membership for
each index based on objective market capitalization rankings and style
attributes. More than $3.9 trillion in assets are currently benchmarked
to the Russell family of indexes.
About Agios Pharmaceuticals, Inc.
Agios Pharmaceuticals is focused on discovering and developing novel
drugs to treat cancer and rare metabolic genetic diseases (known as
inborn errors of metabolism or IEMs) through scientific leadership in
the field of cellular metabolism. In addition to an active research and
discovery pipeline across both therapeutic areas, Agios has multiple
first-in-class lead product candidates in cancer metabolism and IEMs in
clinical and preclinical development. All Agios programs focus on
genetically identified patient populations leveraging our knowledge of
metabolism, biology and genomics. For more information, please visit our
website at www.agios.com.
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements within the
meaning of The Private Securities Litigation Reform Act of 1995. The
words “believe,” “expect” “could,” “should,” “will,” “may” and similar
expressions are intended to identify forward-looking statements,
although not all forward-looking statements contain these identifying
words. Such statements are subject to important risks and uncertainties
that may cause actual events or results to differ materially from Agios’
current expectations and beliefs, including the risks described under
the caption “Risk Factors” in Agios’ Quarterly Report on Form 10-Q for
the quarter ended June 30, 2013 which is on file with the Securities and
Exchange Commission (SEC), and other filings that Agios may make with
the SEC in the future, and other filings that Agios may make with the
SEC in the future. Any forward-looking statements contained in this
press release speak only as of the date hereof, and Agios expressly
disclaims any obligation to update any forward-looking statements,
whether as a result of new information, future events or otherwise.
Source: Agios Pharmaceuticals, Inc.
For Agios Pharmaceuticals, Inc.
Media Contact:
Dan
Budwick, 973-271-6085
dan@purecommunicationsinc.com
or
Investor
Contact:
Glenn Goddard
investors@agios.com
